Effect of Atomoxetine and Oxybutynin on Phenotype Traits and OSA Severity
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Atomoxetine (Primary) ; Oxybutynin (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Acronyms ATOSA
- 17 Jan 2018 Status changed from recruiting to completed.
- 21 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 21 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.